Alglucerase
From Wikipedia, the free encyclopedia
| Image:Alglucerase.png | |
|
Alglucerase
|
|
| Systematic (IUPAC) name | |
| Human Beta-glucocerbrosidase | |
| Identifiers | |
| CAS number | |
| ATC code | A16 |
| PubChem | ? |
| DrugBank | |
| Chemical data | |
| Formula | C2532H3854N672O711S16 |
| Mol. mass | 55597.4 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | 3.6-10.4 min |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Alglucerase is a modified form of human β-glucocerebrosidase where the non-reducing ends of the oligosaccharide chains have been terminated with mannose residues. Ceredase® is a citrate buffered solution of Alglucerase manufactured by Genzyme Corporation from human placental tissue. It is given intravenously in the treatment of Type 1 Gaucher's disease although it has been largely replaced by Cerezyme® which is produced by Recombinant DNA technology.
[edit] External links
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
